Rusfertide Sales Forecast and Market Size Analysis 2020-2025 & 2026-2034

Regulatory momentum supports adoption, while potential use in hemochromatosis and global markets broadens opportunity

Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Rusfertide Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of rusfertide (PTG-300) across polycythemia vera (PV), haemochromatosis and other potential indications involving iron dysregulation. The analysis covers the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.

The report examines rusfertide's clinical development, regulatory progress, market potential, competitive positioning, pricing outlook and forecast sales through 2034. It also evaluates the factors expected to influence physician adoption, patient access and commercial performance following potential regulatory approval.

Key Factors Driving Rusfertide Market Growth

• First-in-class therapeutic approach: Rusfertide is an investigational hepcidin mimetic peptide designed to regulate iron availability for erythropoiesis and reduce excessive red blood cell production in patients with polycythemia vera. Its mechanism may address iron dysregulation while reducing dependence on therapeutic phlebotomy.
• Positive Phase III VERIFY results: The pivotal VERIFY trial met its primary endpoint, with 77% of rusfertide-treated patients achieving a clinical response compared with 33% receiving placebo during Weeks 20-32 (p<0.0001). The trial also met all four key secondary endpoints. Rusfertide-treated patients required an average of 0.5 phlebotomies compared with 1.8 in the placebo group, alongside improved hematocrit control and patient-reported outcomes.
• Durable clinical activity: Long-term findings from the REVIVE and THRIVE extension studies demonstrated sustained efficacy for up to four years, including a 13-fold reduction in the annual therapeutic phlebotomy rate from baseline. Phase III data through 52 weeks, presented at the 2025 American Society of Hematology Annual Meeting, also supported durable hematocrit control without new safety signals.
• Regulatory momentum: In March 2026, the U.S. Food and Drug Administration accepted the New Drug Application for rusfertide and granted Priority Review, with a Prescription Drug User Fee Act Target Action date in the third quarter of 2026. Rusfertide has also received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA.
• Substantial unmet need in polycythemia vera: Approximately 30-40% of patients with PV remain dependent on repeated therapeutic phlebotomies despite standard treatment. If approved, rusfertide could provide an important add-on Option for patients requiring frequent procedures while supporting hematocrit control and quality of life.

Rusfertide Drug and Clinical Overview

Rusfertide is being developed by Protagonist Therapeutics, with Takeda positioned to support its potential commercialization. The therapy is administered as a once-weekly subcutaneous injection and is intended to maintain hematocrit below 45%, reduce therapeutic phlebotomy requirements and mitigate iron deficiency associated with repeated procedures.

Clinical evidence generated to date supports rusfertide's potential role in the long-term management of polycythemia vera. The report evaluates its efficacy, safety, dosage and administration, clinical trial status, expected treatment duration and differentiation from current and emerging therapies.

Scope of the Rusfertide Market Report

• Current and forecast rusfertide sales through 2034 across the 7MM
• Market size analysis for polycythemia vera, haemochromatosis and other potential indications
• Mechanism of Action , dosage, administration and product development overview
• Clinical trial analysis, including study design, interventions, status and completion timelines
• Regulatory milestones, expected launch timing and commercialization strategy
• Rusfertide pricing estimates, reimbursement considerations and regional cost variations
• Patent coverage, exclusivity considerations and potential generic-entry impact
• Competitive landscape and late-stage pipeline analysis
• SWOT analysis, analyst perspectives and market positioning
• Commercial partnerships, licensing agreements and relevant merger and acquisition activity

Rusfertide Market Potential and Competitive Intelligence

The report assesses rusfertide's projected market size, peak sales potential and expected uptake across key geographies. It compares the product's clinical profile with existing treatments and pipeline competitors, identifying potential strengths, limitations, growth barriers and commercial opportunities.

Competitive intelligence includes the number and status of therapies in development, expected launch dates, clinical differentiation and the potential effect of emerging products on rusfertide's market share. The analysis also considers physician prescribing behavior, patient eligibility, reimbursement conditions and regional access dynamics.

Key Questions Addressed

• What are rusfertide's clinical, regulatory and commercial prospects?
• How could FDA designations and Priority Review affect its potential U.S. launch?
• What are the forecast sales and market opportunities for rusfertide across the 7MM?
• How does rusfertide compare with existing treatments and late-stage emerging therapies?
• What pricing, reimbursement and patient-access factors could influence adoption?
• Which partnerships, licensing agreements and development activities are shaping the product's commercial outlook?
• What assumptions support the rusfertide market forecast through 2034?

The report offers strategic insights for pharmaceutical companies, investors, healthcare stakeholders and portfolio decision-makers evaluating the future of rusfertide in polycythemia vera, haemochromatosis and other potential indications associated with iron dysregulation.

Key Topics Covered

1. Report Introduction

2. Rusfertide Overview in potential indication like Polycythaemia vera and Haemochromatosis
2.1. Product Detail
2.2. Rusfertide Clinical Development
2.2.1. Rusfertide Clinical studies
2.2.2. Rusfertide Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile

3. Rusfertide Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Rusfertide Therapies)

5. Rusfertide Market Assessment
5.1. Rusfertide Market Outlook in potential indications
5.2. 7MM Analysis
5.2.1. Rusfertide Market Size in the 7MM for potential indications
5.3. Country-wise Market Analysis
5.3.1. Rusfertide Market Size in the United States for potential indications
5.3.2. Rusfertide Market Size in Germany for potential indications
5.3.3. Rusfertide Market Size in France for potential indications
5.3.4. Rusfertide Market Size in Italy for potential indications
5.3.5. Rusfertide Market Size in Spain for potential indications
5.3.6. Rusfertide Market Size in the United Kingdom for potential indications
5.3.7. Rusfertide Market Size in Japan for potential indications

6. Rusfertide SWOT Analysis

7. Analyst's Views

8. Appendix
8.1. Bibliography
8.2. Report Methodology

List of Tables
Table 1: Rusfertide, Clinical Trial Description, 2023
Table 2: Rusfertide, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: Rusfertide's pricing and cost Assumptions
Table 6: Rusfertide's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: Rusfertide Market Size in the US, in USD million (2020-2034)
Table 8: Rusfertide Market Size in Germany, in USD million (2020-2034)
Table 9: Rusfertide Market Size in France, in USD million (2020-2034)
Table 10: Rusfertide Market Size in Italy, in USD million (2020-2034)
Table 11: Rusfertide Market Size in Spain, in USD million (2020-2034)
Table 12: Rusfertide Market Size in the UK, in USD million (2020-2034)
Table 13: Rusfertide Market Size in Japan, in USD million (2020-2034)

List of Figures
Figure 1: Rusfertide's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: Rusfertide Market Size in the United States, USD million (2020-2034)
Figure 3: Rusfertide Market Size in Germany, USD million (2020-2034)
Figure 4: Rusfertide Market Size in France, USD million (2020-2034)
Figure 5: Rusfertide Market Size in Italy, USD million (2020-2034)
Figure 6: Rusfertide Market Size in Spain, USD million (2020-2034)
Figure 7: Rusfertide Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: Rusfertide Market Size in Japan, USD million (2020-2034)

For more information about this report visit https://www.researchandmarkets.com/r/piw0hd

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900